Titre
Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study.
Type
étude de cas
Institution
Externe
Auteur(s)
Eandi, C.M.
Auteure/Auteur
Ober, M.D.
Auteure/Auteur
Freund, K.B.
Auteure/Auteur
Klais, C.M.
Auteure/Auteur
Slakter, J.S.
Auteure/Auteur
Sorenson, J.A.
Auteure/Auteur
Yannuzzi, L.A.
Auteure/Auteur
Liens vers les personnes
ISSN
0275-004X
Statut éditorial
Publié
Date de publication
2006-09
Volume
26
Numéro
7
Première page
780
Dernière page/numéro d’article
785
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
To investigate the use of anecortave acetate, a new angiostatic cortisene, for the treatment of the leakage and/or neovascularization associated with idiopathic perifoveal telangiectasia (IPT) in an open label prospective pilot study.
Seven eyes of six patients were treated with posterior juxtascleral administration of anecortave acetate delivered adjacent to the macula using a specially designed curved cannula. A full clinical examination and fluorescein angiography were performed at baseline and at 3-month intervals. The primary efficacy outcome for this pilot study was the mean change in visual acuity (Early Treatment Diabetic Retinopathy Study) from baseline.
The visual acuity remained unchanged in two eyes of two patients with nonproliferative disease after 24 months. The five eyes of four patients presenting with subretinal neovascularization, the proliferative stage of IPT, showed stabilization or improvement of lesion size, resolution of leakage, and stabilization of vision at last follow-up.
The results of this study suggest that anecortave acetate may inhibit retinal and subretinal permeability as well as neovascular proliferation in patients with IPT. A larger study accordingly should be designed in the future to evaluate the effectiveness and treatment of IPT with this drug.
Seven eyes of six patients were treated with posterior juxtascleral administration of anecortave acetate delivered adjacent to the macula using a specially designed curved cannula. A full clinical examination and fluorescein angiography were performed at baseline and at 3-month intervals. The primary efficacy outcome for this pilot study was the mean change in visual acuity (Early Treatment Diabetic Retinopathy Study) from baseline.
The visual acuity remained unchanged in two eyes of two patients with nonproliferative disease after 24 months. The five eyes of four patients presenting with subretinal neovascularization, the proliferative stage of IPT, showed stabilization or improvement of lesion size, resolution of leakage, and stabilization of vision at last follow-up.
The results of this study suggest that anecortave acetate may inhibit retinal and subretinal permeability as well as neovascular proliferation in patients with IPT. A larger study accordingly should be designed in the future to evaluate the effectiveness and treatment of IPT with this drug.
PID Serval
serval:BIB_EA4B44AD65CF
PMID
Date de création
2021-03-11T18:50:03.859Z
Date de création dans IRIS
2025-05-21T07:21:58Z